<table>
<thead>
<tr>
<th>Monday 16 November</th>
<th>Tuesday 17 November</th>
<th>Wednesday 18 November</th>
<th>Thursday 19 November</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium 20</strong></td>
<td><strong>Sponsored Symposium Session</strong></td>
<td><strong>Symposium 86</strong></td>
<td><strong>Scientific Session 126</strong></td>
</tr>
<tr>
<td>A Fundamental Way to Prevent Malaria in Pregnancy: Improving Health Outcomes for Pregnant Women and Their Babies One Nurse and Midwife at a Time</td>
<td>Re-starting Malaria R&amp;D in the face of COVID in Africa</td>
<td>Severe Malaria: Improving the Continuum of Care</td>
<td>Malaria: Updates and Innovations in Malaria Prevention</td>
</tr>
<tr>
<td><strong>Poster Session B</strong></td>
<td></td>
<td><strong>Symposium 104</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy</td>
<td></td>
</tr>
</tbody>
</table>
Symposium 20
Meeting room 3
Monday 16 November, 3:00 PM to 4:45 PM EST - 9:00 PM to 10:45 PM CET

A Fundamental Way to Prevent Malaria in Pregnancy: Improving Health Outcomes for Pregnant Women and Their Babies One Nurse and Midwife at a Time

Chair/Co-Chair: Katherine Wolf, MPH, Impact Malaria, Jhpiego, USA; Maurice Bucagu, World Health Organization, Switzerland

Speakers and topics:
- Introduction to the Call to Action in the Year of the Nurse and Midwife
  Pedro Alonso, World Health Organization, Switzerland
- Quality Assured MiP Medicines: An Update on the Supply Side
  Maud Majeres Lugand, MMV, Switzerland
- Using Short Message Service Alerts to Increase Antenatal Care and Malaria Prevention: Findings from Implementation Research Pilot in Guinea
  Aissata Fofana, RTI International, Guinea
- Testing the Feasibility of Community IPTp in Burkina Faso
  Yacouba Ouedraogo, Jhpiego, Burkina Faso
- Effect of Group Antenatal Care (G-ANC) Versus Individual Antenatal Care (ANC) on IPTp and ANC Attendance: A Cluster-Randomized Controlled Trial in Nigeria and Kenya
  Jenipher Ang’aha, Jhpiego, Kenya

Symposium 86
Meeting room 5
Wednesday 18 November, 1:45 PM to 3:30 PM EST - 7:45 PM to 9:30 PM CET

Severe Malaria: Improving the Continuum of Care

Chair/Co-Chair: Hans Rietveld, MMV, Switzerland; Elizabeth Juma, World Health Organization, Africa Regional Office, Zimbabwe

Speakers and topics:
- Behavior-change communication and training of Health Surveillance Assistants to improve severe malaria case-management practices: results from a study in Malawi
  John Phuka, School of Public Health and Family Medicine, College of Medicine, University of Malawi, Malawi
- A rapid assessment of severe malaria case-management practices, including referrals, in Angola
  José Martins, National Malaria Control Program, Direction of Public Health, Angola
- Rolling out artesunate rectal capsules as a pre-referral intervention in Sierra Leone
  Anitta R. Kamara, National Malaria Control Programme, Sierra Leone
- A country experience: training, implementation and process evaluation related to a pre-referral intervention for severe malaria patients in Madagascar
  Mauricette Andriamananjara Nambinisoa, National Malaria Control Program, Madagascar
Symposium 104

Meeting room 6
Wednesday 18 November, 3:45 PM to 5:30 PM EST - 9:45 PM to 11:30 PM CET

Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy

Chair/Co-Chair: Jimee Hwang, CDC, United States; Caroline Lynch, MMV, Switzerland

Speakers and topics:

- New diagnostic tests for *P. vivax*
  Allison L. Golden, PATH, USA

- A clinical research platform for the validation of novel G6PD tests was established across Brazil, Ethiopia, the US
  Daniel Yilma, Jimma University, Ethiopia

- Potential impact of new tools on *P. vivax* malaria
  Michael White, Institut Pasteur, France

- Planned approach to assess the operational feasibility of providing appropriate radical cure after quantitative G6PD testing in Brazil
  Marcus Lacerda, Fiocruz Amazônia/ Tropical Medicine Foundation Dr. Heitor Vieira Dourado, Brazil

- Pathway for policy adoption of new tools for *P. vivax* in Myanmar
  Wint Phyo Than, Vector Borne Disease Control Program, Department of Public Health, Ministry of Health and Sports, Myanmar
Sponsored Symposium Session

Meeting room 2
Tuesday 17 November, 6:45 AM to 8:30 AM EST - 12:45 PM to 2:30 PM CET

Re-starting Malaria R&D in the face of COVID in Africa

Chair/Co-Chair: Dr Abdourahmane Diallo, CEO, The RBM Partnership to End Malaria, Switzerland;
Dr Berhnards Ogutu, Chief Research Officer, Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist, Malaria Clinical Trials Alliance of the INDEPTH-Network, Kenya.

This symposium will share perspectives from research programmes on how COVID-19 has affected their operations and planning for re-starting R&D in a safe and effective manner.

- Mark Chataway, Ireland Baird’s CMC, Ireland
- Dr Abdourahmane Diallo, CEO, The RBM Partnership to End Malaria, Switzerland
- Dr Berhnards Ogutu, Chief Research Officer, Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist, Malaria Clinical Trials Alliance of the INDEPTH-Network, Kenya
- Catherine Kyobutuni, Executive Director African Population and Health Research Centre, Kenya
- Caroline Boulton, Global Programme Head Malaria, Novartis, Switzerland
- David Reddy, CEO, MMV, Switzerland
- Michael Makanga, CEO, EDCTP, Netherlands
- Lacina Koné, Director General, Smart Africa, Rwanda
Scientific Session 126

Malaria: Updates and Innovations in Malaria Prevention

Chair/Co-Chair: Francisco-Javier Gamo, Diseases of the Developing World, GlaxoSmithKline, Spain; Carol H. Sibley, University of Washington, USA

Speakers and topics:

1940  Inhibition of the *Plasmodium falciparum* Acetyl-CoA Synthetase by multiple chemotypes disrupts protein acetylation and epigenetic regulation in blood stage parasites
Robert L. Summers, Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, USA

1498  Prodigiones as Novel Multiple Stage Active Antimalarials with Radical Cure Effect
Papireddy Kancharla, Portland State University, USA

1500  A first in human study to investigate the safety, pharmacokinetics and antimalarial activity of ZY-19489 in the induced blood stage *Plasmodium falciparum* malaria model
Dr Bridget Barber, QIMR, Australia

1501  Evaluation Of The Efficacy and Safety Of Tafenoquine Co-Administered With Dihydroartemisinin-Piperaquine For The Radical Cure (Anti-Relapse) Of Plasmodium vivax Malaria In Indonesia - INSPECTOR Study
Prof Kevin Baird, Eijkman Oxford Clinical Research Unit (EOCRU), Indonesia

1502  A randomized, open-label, non-comparative, multicenter study to assess the pharmacokinetics, safety, and efficacy of tafenoquine in the treatment of pediatric subjects with *Plasmodium vivax* malaria (TEACH study)
Prof Ivan D. Velez, PECET Universidad de Antioquia, Colombia

Poster Session B

Poster hall
Tuesday 17 November, 11:45 AM to 1:15 PM EST - 5:45 PM to 7:15 CET

Speakers and topics:

677  Comparative Efficacy and Safety of Pyronaridine-artsunate versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Malaria Among Children in Southwest Nigeria-an interim report
Catherine Olufunke Falade, University of Ibadan, Nigeria